2025
Utility of computed tomography (CT) –based staging of mismatch repair deficient (dMMR) colon cancer.
Linhares S, Srikumar T, Shin C, Mathur M, Mongiu A, Leeds I, Pantel H, Cecchini M. Utility of computed tomography (CT) –based staging of mismatch repair deficient (dMMR) colon cancer. Journal Of Clinical Oncology 2025, 43: 45-45. DOI: 10.1200/jco.2025.43.4_suppl.45.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsNeoadjuvant immune checkpoint inhibitorsPathological stageDMMR tumorsPMMR tumorsColon cancerSurgical resectionT stageRadiographic stagePathologic complete response rateUtilization of computed tomographyClinically staged patientsNode negative tumorsRate of understagingComplete response rateLocally advanced diseaseNode-positive diseaseClinical tumor stageNode-positive tumorsUpfront surgical resectionCorrelated to pathological stagingPrimary tumor growthLocalized colon cancerLow relapse rateEarly stage tumors
2021
A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability
Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon‐Rosario J, Harold JA, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin JA, Choi J, Santin AD. A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability. Cancer 2021, 128: 1206-1218. PMID: 34875107, PMCID: PMC9465822, DOI: 10.1002/cncr.34025.Peer-Reviewed Original ResearchConceptsObjective response rateImmune checkpoint inhibitorsProgression-free survivalEndometrial cancerWhole-exome sequencingSporadic endometrial cancerOverall survivalEnd pointPhase 2 pilot studyPrimary end pointSecondary end pointsTumor mutation burdenPhase 2 evaluationLarger confirmatory studiesAntigen processing/presentationProcessing/presentationCheckpoint inhibitorsSurgical resectionICI resistanceDMMR patientsPrognostic significanceDMMR tumorsMechanisms of resistanceLocal treatmentSporadic MSI
2020
Metastatic Colorectal Cancers with Mismatch Repair Deficiency Result in Worse Survival Regardless of Peritoneal Metastases
Sherman S, Schuitevoerder D, Chan C, Turaga K. Metastatic Colorectal Cancers with Mismatch Repair Deficiency Result in Worse Survival Regardless of Peritoneal Metastases. Annals Of Surgical Oncology 2020, 27: 5074-5083. PMID: 32583196, PMCID: PMC9782694, DOI: 10.1245/s10434-020-08733-x.Peer-Reviewed Original ResearchConceptsNational Cancer DatabasePeritoneal metastasisAppendix cancerPM patientsPrimary tumorWorse survivalDistant nodal metastasisStage 4 diseaseMetastatic colorectal cancerMMR testingStage 4 patientsColon primary tumorsKaplan-Meier analysisStage 4 colorectal cancerFisher's exact testBackgroundMismatch-repair-deficiencyImmunotherapy useNodal metastasisMetastatic colorectalCancer DatabaseDMMR tumorsTested patientsExact testColorectal adenocarcinomaColorectal cancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply